Welcome to Bio-Link
Bio-Link is a life sciences commercialisation company which facilitates partnerships based on technology review, project management, business development and deal negotiation. Bio-Link has offices in Sydney and Melbourne.
Our clients include Australian biotech companies and medical research institutes. Our portfolio extends across small molecule and peptide drug candidates, genetic and protein biomarkers, gene and cell therapies, immunotherapies and other leading technologies.
Bio-Link adds value to the commercialisation process through critical assessment of patents, packaging of pre-clinical and clinical data, technology marketing and identification and engagement with potential collaborators, licensees, or investors.
Our team has experience in therapeutics and diagnostics and has been involved in a number of commercial transactions in the USA, Europe and Australia.
Please explore this website to gain more information about our team, our stakeholders and our portfolio. And please click here to download our latest newsletter (August 2007).
19th November 2008 - Bio-Link Extends European Network
Dr. David Bancroft, based in Munich, Germany, has joined the Bio-Link Advisory Panel, extending the company's reach into Europe. Dr. Bancroft is a co-founder of GPC Biotech AG and has extensive experience in intellectual property management, drug development and deal-making in Europe and the USA.
Dr. David Bancroft, based in Munich, Germany, has joined the Bio-Link Advisory Panel, extending the company's reach into Europe. Dr. Bancroft is a co-founder of GPC Biotech AG and has extensive experience in intellectual property management, drug development and deal-making in Europe and the USA.
28th August 2008 - Dr. Russell Howard Joins Advisory Panel
Bio-Link is pleased to announce that Dr. Howard, CEO of Maxygen Inc., has joined its Advisory Panel, extending Bio-Link's strategic and deal making capabilities in the USA and other countries.
30th June 2008 - Commercial Deal on POWMRI Parkinson's Test
Bio-Link has facilitated a deal with ASX-listed BioLayer Corporation on the test for early onset Parkinson's developed by Dr. Kay Double at the Prince of Wales Medical Research Institute. Click here for BioLayer's ASX announcement.